Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

Summary

This Expanded Access Protocol will provide access to the IMP ExoFlo for patients who have severe or life-threatening abdominal solid organ transplant rejection or who are evaluated and determined to be at high risk of progression to severe or life-threatening condition related to rejection of an abdominal solid organ transplant, at risk of worsening allograft function, or at risk of complications from current immunosuppressive therapeutic regimens.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications